Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug candidate “foralumab” program entering ...
ZÜRICH--(BUSINESS WIRE)--CDR-Life Inc. today announced an expansion of its pipeline of novel T cell engagers (TCE) with the addition of CDR813 and CDR505. CDR813 is a highly potent and selective TCE ...
Cause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study Healthy volunteers were recruited and underwent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback